Etanercept (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Etanercept" in Italian language version.

refsWebsite

Global rank Italian rank

21nih.gov

4^th place

9^th place

17doi.org

2^nd place

7^th place

15oadoi.org

799^th place

22^nd place

2archive.org

6^th place

8^th place

2fda.gov

447^th place

644^th place

1acrabstracts.org

low place

1archive.today

14^th place

11^th place

1paperity.org

low place

1europa.eu

68^th place

57^th place

1web.archive.org

1^st place

1medscape.org

low place

acrabstracts.org

Davies R, Southwood TR, Kearsley-Fleet L, Lunt M e Hyrich KL, Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study !, in Arthritis Rheumatol, vol. 67, n. 9, settembre 2015, pp. 2487-94, DOI:10.1002/art.39197, PMC 5049649. URL consultato il 30 gennaio 2020 (archiviato il 30 gennaio 2020). Ospitato su PUBMED, paperity.org.

archive.org

TD. van Dijken, SJ. Vastert; VM. Gerloni; I. Pontikaki; K. Linnemann; H. Girschick; W. Armbrust; K. Minden; FH. Prince; FT. Kokke; EE. Nieuwenhuis, Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept., in J Rheumatol, vol. 38, n. 7, luglio 2011, pp. 1441-6, DOI:10.3899/jrheum.100809, PMID 21459936.
JF. Colombel, EV. Loftus; WJ. Tremaine; LJ. Egan; WS. Harmsen; CD. Schleck; AR. Zinsmeister; WJ. Sandborn, The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients., in Gastroenterology, vol. 126, n. 1, gennaio 2004, pp. 19-31, PMID 14699483.

archive.today

Davies R, Southwood TR, Kearsley-Fleet L, Lunt M e Hyrich KL, Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study !, in Arthritis Rheumatol, vol. 67, n. 9, settembre 2015, pp. 2487-94, DOI:10.1002/art.39197, PMC 5049649. URL consultato il 30 gennaio 2020 (archiviato il 30 gennaio 2020). Ospitato su PUBMED, paperity.org.

doi.org

dx.doi.org

Davies R, Southwood TR, Kearsley-Fleet L, Lunt M e Hyrich KL, Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study !, in Arthritis Rheumatol, vol. 67, n. 9, settembre 2015, pp. 2487-94, DOI:10.1002/art.39197, PMC 5049649. URL consultato il 30 gennaio 2020 (archiviato il 30 gennaio 2020). Ospitato su PUBMED, paperity.org.
A. Dallocchio, D. Canioni; F. Ruemmele; A. Duquesne; JY. Scoazec; R. Bouvier; F. Paraf; J. Languepin; CH. Wouters; M. Guillot; P. Quartier, Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study., in Rheumatology (Oxford), vol. 49, n. 9, settembre 2010, pp. 1694-8, DOI:10.1093/rheumatology/keq136, PMID 20472717.
TD. van Dijken, SJ. Vastert; VM. Gerloni; I. Pontikaki; K. Linnemann; H. Girschick; W. Armbrust; K. Minden; FH. Prince; FT. Kokke; EE. Nieuwenhuis, Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept., in J Rheumatol, vol. 38, n. 7, luglio 2011, pp. 1441-6, DOI:10.3899/jrheum.100809, PMID 21459936.
M. Baghai, DR. Osmon; DM. Wolk; LE. Wold; GJ. Haidukewych; EL. Matteson, Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept., in Mayo Clin Proc, vol. 76, n. 6, Giu 2001, pp. 653-6, DOI:10.4065/76.6.653, PMID 11393506.
A. Kling, T. Mjörndal; S. Rantapää-Dahlqvist, Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNFalpha antagonists., in J Clin Rheumatol, vol. 10, n. 3, giugno 2004, pp. 119-22, DOI:10.1097/01.rhu.0000128734.07926.8e, PMID 17043483.
N. Ikumi, Y. Matsukawa; Y. Kuwana; H. Kodaira; T. Tanaka; N. Maruyama; S. Nozawa; A. Horikoshi; J. Takeuchi, Staphylococcus aureus sepsis after etanercept induction in a hemodialysis patient., in Hemodial Int, vol. 17, n. 1, gennaio 2013, pp. 133-5, DOI:10.1111/j.1542-4758.2012.00723.x, PMID 22742581.
EJ. Lee, R. Song; JN. Park; YA. Lee; JS. Son; SJ. Hong; HI. Yang; SH. Lee, Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor., in Int J Rheum Dis, vol. 13, n. 3, agosto 2010, pp. e16-9, DOI:10.1111/j.1756-185X.2010.01528.x, PMID 20704604.
JH. Lee, NR. Slifman; SK. Gershon; ET. Edwards; WD. Schwieterman; JN. Siegel; RP. Wise; SL. Brown; JN. Udall; MM. Braun, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept., in Arthritis Rheum, vol. 46, n. 10, ottobre 2002, pp. 2565-70, DOI:10.1002/art.10583, PMID 12384912.
NR. Slifman, SK. Gershon; JH. Lee; ET. Edwards; MM. Braun, Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents., in Arthritis Rheum, vol. 48, n. 2, febbraio 2003, pp. 319-24, DOI:10.1002/art.10758, PMID 12571839.
J. Bourré-Tessier, C. Fortin; A. Belisle; E. Desmarais; D. Choquette; JL. Senécal, Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept., in Scand J Rheumatol, vol. 38, n. 4, 2009, pp. 311-6, DOI:10.1080/03009740902776935, PMID 19444717.
A. Strangfeld, J. Listing; P. Herzer; A. Liebhaber; K. Rockwitz; C. Richter; A. Zink, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents., in JAMA, vol. 301, n. 7, febbraio 2009, pp. 737-44, DOI:10.1001/jama.2009.146, PMID 19224750.
P. McCroskery, CA. Wallace; DJ. Lovell; S. Stryker; N. Chernyukhin; C. Blosch; DJ. Zack, Summary of worldwide pediatric malignancies reported after exposure to etanercept., in Pediatr Rheumatol Online J, vol. 8, 2010, p. 18, DOI:10.1186/1546-0096-8-18, PMID 20546618.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group., Etanercept plus standard therapy for Wegener's granulomatosis., in N Engl J Med, vol. 352, n. 4, gennaio 2005, pp. 351-61, DOI:10.1056/NEJMoa041884, PMID 15673801.
JH. Stone, JT. Holbrook; MA. Marriott; AK. Tibbs; LP. Sejismundo; YI. Min; U. Specks; PA. Merkel; R. Spiera; JC. Davis; EW. St Clair, Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial., in Arthritis Rheum, vol. 54, n. 5, Mag 2006, pp. 1608-18, DOI:10.1002/art.21869, PMID 16646004.
F. Silva, P. Seo; DR. Schroeder; JH. Stone; PA. Merkel; GS. Hoffman; R. Spiera; JK. Sebastian; JC. Davis; EW. St Clair; NB. Allen, Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort., in Arthritis Rheum, vol. 63, n. 8, Ago 2011, pp. 2495-503, DOI:10.1002/art.30394, PMID 21484770.
E. Bonilla, YY. Lee; PE. Phillips; A. Perl, Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus., in Ann Rheum Dis, vol. 66, n. 12, dicembre 2007, p. 1688, DOI:10.1136/ard.2007.072256, PMID 17998221.
MC. Genovese, S. Cohen; L. Moreland; D. Lium; S. Robbins; R. Newmark; P. Bekker, Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate., in Arthritis Rheum, vol. 50, n. 5, maggio 2004, pp. 1412-9, DOI:10.1002/art.20221, PMID 15146410.

europa.eu

ema.europa.eu

Scheda Prodotto Enbrel, 2012, disponibile online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000262/human_med_000764.jsp&mid=WC0b01ac058001d124

fda.gov

FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy, su fda.gov, Food and Drug Administration, 11 marzo 2011. URL consultato il 12 giugno 2013.
Onyeka Otugo, Olabode Ogundare, Christopher Vaughan, Emmanuel Fadiran, Leyla Sahin, Consistency of Pregnancy Labeling Across Different Therapeutic Classes (PDF), su fda.gov, Food and Drug Administration - Office of Women’s Health, 1979. URL consultato il 27 giugno 2013.

medscape.org

Abatacept Plus Etanercept Should Not Be Used for Rheumatoid Arthritis Therapy, su medscape.org, Medscape Education, 5 settembre 2006. URL consultato il 12 maggio 2013.

nih.gov

ncbi.nlm.nih.gov

Davies R, Southwood TR, Kearsley-Fleet L, Lunt M e Hyrich KL, Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study !, in Arthritis Rheumatol, vol. 67, n. 9, settembre 2015, pp. 2487-94, DOI:10.1002/art.39197, PMC 5049649. URL consultato il 30 gennaio 2020 (archiviato il 30 gennaio 2020). Ospitato su PUBMED, paperity.org.
A. Dallocchio, D. Canioni; F. Ruemmele; A. Duquesne; JY. Scoazec; R. Bouvier; F. Paraf; J. Languepin; CH. Wouters; M. Guillot; P. Quartier, Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study., in Rheumatology (Oxford), vol. 49, n. 9, settembre 2010, pp. 1694-8, DOI:10.1093/rheumatology/keq136, PMID 20472717.
TD. van Dijken, SJ. Vastert; VM. Gerloni; I. Pontikaki; K. Linnemann; H. Girschick; W. Armbrust; K. Minden; FH. Prince; FT. Kokke; EE. Nieuwenhuis, Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept., in J Rheumatol, vol. 38, n. 7, luglio 2011, pp. 1441-6, DOI:10.3899/jrheum.100809, PMID 21459936.
M. Baghai, DR. Osmon; DM. Wolk; LE. Wold; GJ. Haidukewych; EL. Matteson, Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept., in Mayo Clin Proc, vol. 76, n. 6, Giu 2001, pp. 653-6, DOI:10.4065/76.6.653, PMID 11393506.
A. Kling, T. Mjörndal; S. Rantapää-Dahlqvist, Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNFalpha antagonists., in J Clin Rheumatol, vol. 10, n. 3, giugno 2004, pp. 119-22, DOI:10.1097/01.rhu.0000128734.07926.8e, PMID 17043483.
C. Nuñez-Cornejo, J. Borrás-Blasco; A. Gracia-Perez; JD. Rosique-Robles; V. Lopez-Camps; E. Casterã; FJ. Abad, Septic shock and community-acquired pneumonia associated with etanercept therapy., in Int J Clin Pharmacol Ther, vol. 46, n. 4, aprile 2008, pp. 193-7, PMID 18397693.
N. Ikumi, Y. Matsukawa; Y. Kuwana; H. Kodaira; T. Tanaka; N. Maruyama; S. Nozawa; A. Horikoshi; J. Takeuchi, Staphylococcus aureus sepsis after etanercept induction in a hemodialysis patient., in Hemodial Int, vol. 17, n. 1, gennaio 2013, pp. 133-5, DOI:10.1111/j.1542-4758.2012.00723.x, PMID 22742581.
S. Lassoued, S. Sire; M. Farny; T. Billey; K. Lassoued, Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept., in Clin Exp Rheumatol, vol. 22, n. 2, pp. 267-8, PMID 15083902.
EJ. Lee, R. Song; JN. Park; YA. Lee; JS. Son; SJ. Hong; HI. Yang; SH. Lee, Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor., in Int J Rheum Dis, vol. 13, n. 3, agosto 2010, pp. e16-9, DOI:10.1111/j.1756-185X.2010.01528.x, PMID 20704604.
JH. Lee, NR. Slifman; SK. Gershon; ET. Edwards; WD. Schwieterman; JN. Siegel; RP. Wise; SL. Brown; JN. Udall; MM. Braun, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept., in Arthritis Rheum, vol. 46, n. 10, ottobre 2002, pp. 2565-70, DOI:10.1002/art.10583, PMID 12384912.
NR. Slifman, SK. Gershon; JH. Lee; ET. Edwards; MM. Braun, Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents., in Arthritis Rheum, vol. 48, n. 2, febbraio 2003, pp. 319-24, DOI:10.1002/art.10758, PMID 12571839.
JF. Colombel, EV. Loftus; WJ. Tremaine; LJ. Egan; WS. Harmsen; CD. Schleck; AR. Zinsmeister; WJ. Sandborn, The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients., in Gastroenterology, vol. 126, n. 1, gennaio 2004, pp. 19-31, PMID 14699483.
J. Bourré-Tessier, C. Fortin; A. Belisle; E. Desmarais; D. Choquette; JL. Senécal, Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept., in Scand J Rheumatol, vol. 38, n. 4, 2009, pp. 311-6, DOI:10.1080/03009740902776935, PMID 19444717.
A. Strangfeld, J. Listing; P. Herzer; A. Liebhaber; K. Rockwitz; C. Richter; A. Zink, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents., in JAMA, vol. 301, n. 7, febbraio 2009, pp. 737-44, DOI:10.1001/jama.2009.146, PMID 19224750.
P. McCroskery, CA. Wallace; DJ. Lovell; S. Stryker; N. Chernyukhin; C. Blosch; DJ. Zack, Summary of worldwide pediatric malignancies reported after exposure to etanercept., in Pediatr Rheumatol Online J, vol. 8, 2010, p. 18, DOI:10.1186/1546-0096-8-18, PMID 20546618.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group., Etanercept plus standard therapy for Wegener's granulomatosis., in N Engl J Med, vol. 352, n. 4, gennaio 2005, pp. 351-61, DOI:10.1056/NEJMoa041884, PMID 15673801.
JH. Stone, JT. Holbrook; MA. Marriott; AK. Tibbs; LP. Sejismundo; YI. Min; U. Specks; PA. Merkel; R. Spiera; JC. Davis; EW. St Clair, Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial., in Arthritis Rheum, vol. 54, n. 5, Mag 2006, pp. 1608-18, DOI:10.1002/art.21869, PMID 16646004.
F. Silva, P. Seo; DR. Schroeder; JH. Stone; PA. Merkel; GS. Hoffman; R. Spiera; JK. Sebastian; JC. Davis; EW. St Clair; NB. Allen, Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort., in Arthritis Rheum, vol. 63, n. 8, Ago 2011, pp. 2495-503, DOI:10.1002/art.30394, PMID 21484770.
R. Sannerstedt, P. Lundborg; BR. Danielsson; I. Kihlström; G. Alván; B. Prame; E. Ridley, Drugs during pregnancy: an issue of risk classification and information to prescribers., in Drug Saf, vol. 14, n. 2, febbraio 1996, pp. 69-77, PMID 8852521.
E. Bonilla, YY. Lee; PE. Phillips; A. Perl, Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus., in Ann Rheum Dis, vol. 66, n. 12, dicembre 2007, p. 1688, DOI:10.1136/ard.2007.072256, PMID 17998221.
MC. Genovese, S. Cohen; L. Moreland; D. Lium; S. Robbins; R. Newmark; P. Bekker, Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate., in Arthritis Rheum, vol. 50, n. 5, maggio 2004, pp. 1412-9, DOI:10.1002/art.20221, PMID 15146410.

oadoi.org

A. Dallocchio, D. Canioni; F. Ruemmele; A. Duquesne; JY. Scoazec; R. Bouvier; F. Paraf; J. Languepin; CH. Wouters; M. Guillot; P. Quartier, Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study., in Rheumatology (Oxford), vol. 49, n. 9, settembre 2010, pp. 1694-8, DOI:10.1093/rheumatology/keq136, PMID 20472717.
M. Baghai, DR. Osmon; DM. Wolk; LE. Wold; GJ. Haidukewych; EL. Matteson, Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept., in Mayo Clin Proc, vol. 76, n. 6, Giu 2001, pp. 653-6, DOI:10.4065/76.6.653, PMID 11393506.
A. Kling, T. Mjörndal; S. Rantapää-Dahlqvist, Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNFalpha antagonists., in J Clin Rheumatol, vol. 10, n. 3, giugno 2004, pp. 119-22, DOI:10.1097/01.rhu.0000128734.07926.8e, PMID 17043483.
N. Ikumi, Y. Matsukawa; Y. Kuwana; H. Kodaira; T. Tanaka; N. Maruyama; S. Nozawa; A. Horikoshi; J. Takeuchi, Staphylococcus aureus sepsis after etanercept induction in a hemodialysis patient., in Hemodial Int, vol. 17, n. 1, gennaio 2013, pp. 133-5, DOI:10.1111/j.1542-4758.2012.00723.x, PMID 22742581.
EJ. Lee, R. Song; JN. Park; YA. Lee; JS. Son; SJ. Hong; HI. Yang; SH. Lee, Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor., in Int J Rheum Dis, vol. 13, n. 3, agosto 2010, pp. e16-9, DOI:10.1111/j.1756-185X.2010.01528.x, PMID 20704604.
JH. Lee, NR. Slifman; SK. Gershon; ET. Edwards; WD. Schwieterman; JN. Siegel; RP. Wise; SL. Brown; JN. Udall; MM. Braun, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept., in Arthritis Rheum, vol. 46, n. 10, ottobre 2002, pp. 2565-70, DOI:10.1002/art.10583, PMID 12384912.
NR. Slifman, SK. Gershon; JH. Lee; ET. Edwards; MM. Braun, Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents., in Arthritis Rheum, vol. 48, n. 2, febbraio 2003, pp. 319-24, DOI:10.1002/art.10758, PMID 12571839.
J. Bourré-Tessier, C. Fortin; A. Belisle; E. Desmarais; D. Choquette; JL. Senécal, Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept., in Scand J Rheumatol, vol. 38, n. 4, 2009, pp. 311-6, DOI:10.1080/03009740902776935, PMID 19444717.
A. Strangfeld, J. Listing; P. Herzer; A. Liebhaber; K. Rockwitz; C. Richter; A. Zink, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents., in JAMA, vol. 301, n. 7, febbraio 2009, pp. 737-44, DOI:10.1001/jama.2009.146, PMID 19224750.
P. McCroskery, CA. Wallace; DJ. Lovell; S. Stryker; N. Chernyukhin; C. Blosch; DJ. Zack, Summary of worldwide pediatric malignancies reported after exposure to etanercept., in Pediatr Rheumatol Online J, vol. 8, 2010, p. 18, DOI:10.1186/1546-0096-8-18, PMID 20546618.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group., Etanercept plus standard therapy for Wegener's granulomatosis., in N Engl J Med, vol. 352, n. 4, gennaio 2005, pp. 351-61, DOI:10.1056/NEJMoa041884, PMID 15673801.
JH. Stone, JT. Holbrook; MA. Marriott; AK. Tibbs; LP. Sejismundo; YI. Min; U. Specks; PA. Merkel; R. Spiera; JC. Davis; EW. St Clair, Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial., in Arthritis Rheum, vol. 54, n. 5, Mag 2006, pp. 1608-18, DOI:10.1002/art.21869, PMID 16646004.
F. Silva, P. Seo; DR. Schroeder; JH. Stone; PA. Merkel; GS. Hoffman; R. Spiera; JK. Sebastian; JC. Davis; EW. St Clair; NB. Allen, Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort., in Arthritis Rheum, vol. 63, n. 8, Ago 2011, pp. 2495-503, DOI:10.1002/art.30394, PMID 21484770.
E. Bonilla, YY. Lee; PE. Phillips; A. Perl, Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus., in Ann Rheum Dis, vol. 66, n. 12, dicembre 2007, p. 1688, DOI:10.1136/ard.2007.072256, PMID 17998221.
MC. Genovese, S. Cohen; L. Moreland; D. Lium; S. Robbins; R. Newmark; P. Bekker, Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate., in Arthritis Rheum, vol. 50, n. 5, maggio 2004, pp. 1412-9, DOI:10.1002/art.20221, PMID 15146410.

paperity.org

Davies R, Southwood TR, Kearsley-Fleet L, Lunt M e Hyrich KL, Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study !, in Arthritis Rheumatol, vol. 67, n. 9, settembre 2015, pp. 2487-94, DOI:10.1002/art.39197, PMC 5049649. URL consultato il 30 gennaio 2020 (archiviato il 30 gennaio 2020). Ospitato su PUBMED, paperity.org.

web.archive.org

FDA Pregnancy Categories (PDF), su depts.washington.edu. URL consultato l'11 giugno 2013 (archiviato dall'url originale il 14 dicembre 2010).